New Study Findings from First Affiliated Hospital of Anhui Medical University Illuminate Research in Acute Myeloid Leukemia (Efficacy and Safety of Low-Dose Venetoclax Combined with Voriconazole Inpatients with Acute Myeloid Leukemia Unfit for...).

A recent study conducted at the First Affiliated Hospital of Anhui Medical University in China explored the efficacy and safety of low-dose venetoclax combined with voriconazole in patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. The study found that the combination of low-dose venetoclax and voriconazole was well-tolerated and effective in these patients. The researchers suggest that this concurrent application of venetoclax could be a feasible and sustainable strategy for low-income patients who struggle with the high costs of venetoclax. The study analyzed the efficacy, peak venetoclax concentration, and side effects of the patients in two different cohorts and found no significant differences between them. [Extracted from the article]